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General Introduction
1.1 Chemical Biology
Chemical biology utilizes chemical compounds to regulate the functions of genetic
products and elucidate the molecular mechanisms underlying biological events [1]. Over
recent years, the field of chemical biology has received a large amount of attention from
researchers in life sciences. In this section, the author first describes classical genetics,
a method used to uncover the relationship between genes and their phenotype. The
author then describes the usefulness of chemical compounds in both medicine and basic
research. Finally, the concept of chemical genetics is introduced, which combines the
usefulness of compounds with the theories of classical genetics.
1.1.1 Classical Genetics
Classical genetics has so far elucidated a wide variety of molecular mechanisms that
underlie biological processes. Two approaches are used to uncover such mechanisms,
namely forward genetics and reverse genetics. Forward genetics uses random muta-
genesis and isolates individual mutations that di↵er from a wild-type phenotype [2].
By identifying the mutated gene locus, the genes responsible for the phenotype of
interest can be identified. For example, using this method researchers have uncov-
ered the molecular mechanisms underlying the process of the cell division in the
yeast Saccharomyces cerevisiae [3], embryonic pattern formation in the fly Drosophila
melanogaster [4], and programmed cell-death in the nematode Caenorhabditis ele-
gans [5]. On the other hand, reverse genetics focuses on the functions of the genes
of interest and then mutates or alters their expressions to see what phenotypic changes
occur. To this end, targeted mutagenesis [6–8], transgenic [9,10], or RNA interference
technology [11,12] have been made available.
However, there are still some limitations for classical genetics. First, classical ge-
netics is not e↵ective for use in analyzing higher vertebrates, especially for mammals,
because their rate of reproduction is too slow to perform high-throughput screen-
ings [13, 14]. Second, most higher organisms have a diploid genome and a variety
of isoforms; therefore, there is a possibility that a single mutation of a gene locus will
not be su cient to cause a phenotypic change. Third, most of the mutations performed
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using classical genetic technologies are not conditional. Of course, some new technolo-
gies are now emerging that circumvent this issue; for example, the Cre/LoxP [15, 16]
and CRISPR/Cas9 systems [17,18], which have the potential to be conditional by using
inducible promoters such as heat shock or organ-specific promoters. However, these
systems require the expression of Cre recombinase or Cas9 nuclease and this could
lead to a time lag between the onset of mutagenesis and the loss/gain of gene func-
tion. In addition, these systems could cause environmental stress to the organisms and
confound the interpretation of the results [19].
1.1.2 The Use of Chemical Compounds
Chemical compounds produced by microorganisms have provided enormous benefits
for mankind. Compounds are useful for both medicine and basic research. One of the
triggers that facilitated the therapeutic use of compounds was the discovery of penicillin
by Fleming in the 1940s [20]. Fleming happened to find that the microorganism Peni-
cillium notatum demonstrated anti-bacterial e↵ects and was able to isolate penicillin
for use as an antibacterial substance. Various chemical modifications were then made
to improve the medical properties and the yield of penicillin [21]. Penicillin helped a
large number of people who su↵ered from infections such as pneumonia, gonorrhea,
and rheumatic fever during World War II [22]. Since there was no e↵ective treatment
for these infections at the time, penicillin served as an excellent example demonstrat-
ing that the identification of natural compounds produced by microorganisms and the
modification of these compounds allows for their potential as medicines to treat hu-
man diseases. As a more recent example, Dr. Satoshi Omura received the Nobel Prize
in 2015 for the discovery of ivermectin, which has a therapeutic e↵ect on infections
caused by roundworm parasites [23, 24]. Therefore, many pharmaceutical companies
have sought after finding compounds originating from microorganisms such as fungi,
bacteria, plants, and marine sponges in order to develop new medicines [25–29].
Chemical compounds may also be used for basic research. Since the e↵ects of these
compounds are generally a result of their direct binding to target proteins, they are
useful in altering the function of a gene. Therefore, bioactive compounds, which a↵ect
the phenotype or the molecular function of interest, serve as useful tools to elucidate the
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molecular mechanisms underlying biological processes of interest. In recent years, the
approach of using these compounds for studying biological systems has been referred
to as chemical genetics [1], which I will describe further in the next section.
1.1.3 Chemical Genetics
Chemical genetics was proposed by Dr. Stuart L. Schreiber of Harvard University
[1,13]. Dr. Schreiber assumed that the use of bioactive compounds is equivalent to the
gene mutagenesis used in classical genetics because bioactive compounds can inhibit
or activate the gene of interest. Like classical genetics, there are two approaches used
in chemical genetics: forward and reverse chemical genetics (Fig. 1.1).
Forward chemical genetics employs “phenotype-based” screens [30], where chemical
libraries are used to identify compounds that a↵ect biological processes of interest such
as cell death or embryonic development, and the target proteins of the compounds are
then identified [31]. In forward chemical genetics, researchers attempt to identify the
novel molecules responsible for the phenotype of interest. For example, Dr. Schreiber
demonstrated that calcineurin plays a role in T lymphocyte signal transduction. This
was done by the identification of the inhibitor of T lymphocyte signal transduction,
FK506, and the identification of the FK506 binding protein, calcineurin [32, 33]. On
the other hand, reverse chemical genetics employs the use of “target-based” screens,
where compounds that inhibit or activate the gene of interest are used to see what
phenotypic changes occur. In reverse chemical genetics, researchers expect to identify
the novel functions of a gene of interest in a cellular context.
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Figure 1.1. Chemical Genetics: Similar to classical genetics, there are two ap-
proaches for chemical genetics: forward and reverse chemical genetics. Forward chem-
ical genetics employs “phenotype-based” screens to identify compounds and its target
gene. This approach makes it possible to identify the unexpected gene responsible for
the phenotype. On the other hand, reverse chemical genetics employs “target-based”
screens to reveal the unexpected function of gene of interest. Image adapted from [13].
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Compared to classical genetics, chemical compounds possesses some advantages.
First, compounds are easy to handle. In contrast to the gene mutagenesis of classical
genetics, compounds can be easily used to modulate biological functions in living cells
and animals by simply changing their concentration and the timing of the treatment.
In addition, by washing out the compound from the culture media, the function of
the gene of interest can be reversibly examined. Second, the time lag between the
initiation of the compound treatment and of their loss/gain of function is minimal.
This contrasts with classical genetics, wherein gene mutation takes a greater amount
of time because of the requirement for the expression of CRE recombinase or DNA
nuclease for the purpose of gene mutation. Third, compounds can easily inhibit the
functions of genes whose functions are di cult to examine by simply introducing one
instance of the mutation. Finally, compounds might function as a “bunch of keys”
to inhibit or activate multiple isoforms that have common active regions where the
compounds may bind to. Therefore, although the genetic mutation of one isoform in
classical genetics is not su cient to cause a mutant phenotype, one compound might
be enough to observe a phenotypic change. This is particularly advantageous for higher
vertebrates, which have more isoforms than lower vertebrates.
Conversely, there are also some disadvantages of chemical genetics. In particular,
the target identification of the compounds is a di cult and rate-limiting step in chem-
ical genetics. There are several methods that may be used for target identification
(Fig. 1.2), but no universal method for target identification has yet been found. This
would be due to one of the following reasons: the compound-target protein binding is
weak or transient such that the expression levels of the target proteins are too low to
detect; the extraction bu↵ers or methods used to examine the cell lysate containing
the compound-target protein complexes are not adequate; or the tags attached to the
compound hinder the interaction of the compound with the target.
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Much e↵ort has recently been made to improve these target identification methods
with the introduction of FG-beads technology [34, 35], photoa nity beads technology
[36], polyproline-rod approach [37], and the yeast 3-hybrid system [38]. In Japan, these
or other approaches have been discussed and improved upon in a national project:
“Chemical Biology of Natural Products: Target ID and Regulation of Bioactivity”, as
supported by the Ministry of Education, Culture, Sports, Science, and Technology [39].
Therefore, in the near future, target identification will be made easier.
A B
C
Figure 1.2. Methods of target identification of chemical compounds: (A)
Target identification using a nity beads such as Biotin tag. Target protein can be de-
tected by mixing the cell lysate and tagged compounds, and pulling down the tagged
compounds. (B) Drug A nity Responsive Target Stability (DARTS) method intro-
duced by Huang group [40–42]. This method utilizes the feature of stability of the
target protein directly bound with compounds which are less susceptible to protease
than other non-target proteins. (C) Proteins of interest with fluorescent marker are
used to screen a compound in a chemical array. Image adapted from [43].
Another negative aspect of chemical genetics is the requirement for the prepara-
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tion of derivatives of the compound. In target identification, tagged compounds are
generally required to identify the target protein. In addition, to determine where to
attach these tags, a wide variety of derivatives must be prepared to perform structure-
activity relationship (SAR) experiments. Furthermore, these chemical compounds can
be prepared only when biologists can work in conjunction with chemists. However,
considering the development of new biological tools and medicines, the involvement of
chemists would be ultimately indispensable.
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1.2 Developmental Biology
Developmental biology has served to elucidate the mechanisms of fundamental life
processes using various model animals. In this section, the author first describes several
notable examples for the use of developmental animals. Next, the author introduces
ascidian Ciona robusta, an invertebrate that demonstrates similar early development
characteristics to those of vertebrates. In this thesis, the author performed two chemical
biological studies using Ciona: 1) the establishment of a chemical toxicity evaluation
system using Ciona and 2) the elucidation of the molecular mechanisms of Ciona
notochord tubulogenesis using a chemical genetics approach. Thereby the author will
provide overviews of chemical toxicity evaluations and tubulogenesis.
1.2.1 Invertebrate and vertebrate model animals
Model animals have been used in applied medical research to develop new medicines,
and have been used in basic research to elucidate the mechanisms of fundamental life
processes. There are many kinds of model animals that may be used according to the
type of research.
In applied medical research, higher vertebrate animals such asMus musculus, Rattus
norvegicus, or Callithrix jacchus have been used. Since these animals are more similar
to humans, they provide us invaluable insights into human health and disease. For
example, Mus musculus is a representative model animal that may be used to predict
the therapeutic e↵ect of candidate drugs for treatment of human cancers. This can
be done by implanting human cancers into a nude mouse and assessing the volume
of cancer-causing agents remaining after the candidate drugs have been administered.
Simultaneously, the evaluation of toxicity may also be used to examine body weight.
In the field of neuroscience, Callithrix jacchus is a recently emerging model animal.
In particular, to meet the demand for the development of new therapeutic methods
to treat spinal cord injury, this animal is used to assess functional recovery, combined
with regenerative techniques such as the use of iPS cells [44].
In basic research, lower invertebrate model animals such as Drosophila melanogaster
and Caenorhabditis elegans have been frequently used, taking advantage of their short
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life cycle, simple body plan, low husbandry costs, and large numbers of individuals. For
example, Ernst Hafen, Michael Levine, and William McGinnis discovered a homeobox
from Drosophila melanogaster in 1983 [45–47]. A homeobox is a now well-known DNA
sequence involved in the regulation of patterns of morphogenesis and is a well-conserved
domain found in many other animals. In 1993, Robert Horvitz and colleagues discov-
ered the cell death gene, ced-3, from the developmental process of nematode [48]. After
the discovery of ced-3, other mammalian caspases were subsequently identified. Now,
caspases are widely recognized as important regulators of apoptosis and are extensively
studied, especially in the field of cancer. Another topic discovered in recent years is
regeneration. Planarian proved useful in determining the common mechanisms of re-
generation as planarian that is cut into two pieces may both regenerate into complete
organisms through morphallaxis [49, 50]. As such, invertebrate model animals may be
used to provide a large amount of fundamental knowledge.
1.2.2 Ciona robusta
Ascidian Ciona robusta [51] is a tunicate, a type of marine invertebrate, and has long
been used as a model animal in developmental biology [52,53]. Adult Ciona animals are
widely observed in shallow ocean waters around the world. Despite it being an inverte-
brate, Ciona is recognized as the closest living relative of vertebrates since Kowalevsky
showed that ascidian larvae express the general appearance of a vertebrate tadpole over
150 years ago [51]. In 2002, the draft genome sequence of Ciona was reported [54],
and as a result various genetics tools are now available [55] such as the introduction of
plasmid DNA or mRNA by microinjection or electroporation, morpholino antisense me-
diated knockdown, or the recently developed TALEN [56–58] or CRISPR/Cas9 [59,60]
mediated knockout.
Ciona has several advantages when used as a model animal in developmental biol-
ogy. First, Ciona has a simple body plan (Fig. 1.3). During the tadpole larva stage,
Ciona has a small number of cells, roughly 2500, and its transparent body makes it
suitable for observation. This makes it possible to trace the cell lineage of most major
organs. Second, it is easy to obtain large numbers of larvae by just one fertilization.
Third, husbandry costs are low compared to other vertebrate animals. Fourth, the
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Ciona genome is small, nearly 20 times smaller than the human genome; this simple
genomic organization is advantageous for examining the function of particular genes
with fewer isoforms. Fifth, Ciona demonstrates rapid early development. Within 24
hours after fertilization, Ciona become vertebrate-like in appearance, as a swimming
larva with a notochord and a nerve in its tail [61]. Finally, ethical issues are lessened
for Ciona because it is an invertebrate and therefore lacks pain-related channels [62].
Considering these advantages, Ciona has been extensively used in the studies of cellular
morphogenesis and the development of the heart, notochord, and nervous system for
over a century.
A B
Figure 1.3. Confocal images of Ciona larvae (late tailbud): Cross section (A)
and projection (B) picture of Ciona larva. Ciona become vertebrate-like tadpole larvae
and has several organs including brain, nerve cord notochord, epidermis, endoderm.
Image adapted from [61].
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1.2.3 Toxicity Evaluation
Toxicity indicates the degree to which living organisms are damaged by certain kinds
of chemicals, and is classified into two types: acute and chronic toxicity [63,64]. Acute
toxicity is caused by one-time exposure to a large amount of chemicals, often resulting in
an emergency situation. For example, tetrodotoxin is a potent neurotoxin that exists in
the liver and sex organs of pu↵erfish, and upon exposure to humans can cause vomiting,
arrhythmia, breathing problems, muscle paralysis, and, at worst, death [65]. On the
other hand, chronic toxicity is mainly caused by repeated and long-term exposure, and
includes carcinogenicity, reproductive toxicity, and developmental toxicity. Dioxins are
one of the most well-known chronic toxins produced by improper waste incineration or
natural processes resulting from forest fires [66]. Most dioxins are taken into our body
through food and have the potential to cause developmental and reproductive toxicity,
or even cancer.
Toxicity evaluation is an important step in the development of new drugs and
pesticides [67, 68]. Pharmaceutical companies perform toxicity evaluations and make
their best e↵orts so as not to sell “poisons” to patients su↵ering from diseases. Drugs
with unexpected lethal side e↵ects could lead to devastating outcomes for both patients
and pharmaceutical companies. Some di culties exist, however, in the assessment of
toxicity. Namely, a wide variety of chemical toxicity exists in nature, as described
above, and toxicity information cannot be directly obtained from the human body. As
such, researchers perform many kinds of toxicity tests using various in vitro cell lines
or in vivo model animals. The most reliable tests make use of mammalian animals
including rats, mice, monkeys, or rabbits, and can be used to predict the e↵ects of
toxicity in humans. However, these tests are costly and time-consuming and are not
suitable for the initial assessment of chemical safety. Recently, other “a↵ordable”
model animals, such as zebrafish or Caenorhabditis elegans, have begun to be used for
the identification of drugs that express have low toxicity e↵ects.
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1.2.4 Tubulogenesis
Biological tubes are found in many organs including in the lungs, liver, gut, blood
vessels, and kidneys of most multi-cellular organisms, playing roles in the exchange
of biological materials and structural support. Tubulogenesis, the formation process
of a tube, requires complex cellular morphological changes and therefore fascinates
developmental biologists [69–73]. Knowledge of the mechanisms of tubulogenesis is also
important for physicians because improper tubulogenesis leads to pathological tubular
structures such as polycystic kidney diseases. Furthermore, the growing interest in
regenerative medicine raises the compelling question of how individual cells form a
three-dimensional tube. Considering these contexts, researchers have recently begun
to conduct studies concerning tubulogenesis.
Tubulogenesis proceeds with apico-basal polarization, reorganization of the cy-
toskeleton, apical membrane tra cking, and lumen formation. The establishment of
apical-basal polarization is the first critical step in tubulogenesis [74]. Biological tubes
consist of a central lumen surrounded by a single layer of epithelium. The apical mem-
brane refers to the membrane surrounding the central lumen, and the basal membrane
refers to the opposite site to apical membrane, contacting with extracellular matrix.
How to specify the apical and basal membrane during tubulogenesis, and how to syn-
chronize the polarization among neighboring cells, are long-standing questions. One
of the clues that may be used for the establishment and maintenance of such polarity
would be provided by the outer environment cues from receptors in the extracellular
matrix, such as  1-integrin [75], or adhesive molecules in neighboring cells, such as
cadherins [76]. By responding to these cues, Rho GTPases including RhoA, Rac1, and
Cdc42, as well as PAR complex proteins comprised of Par3, Par6, and aPKC, crosstalk
to play integral roles in the reorganization of the cytoskeleton coordinated by three
kinds of filaments: actin filaments, microtubules, and intermediate filaments. Together
with changes in cell shape, apical membrane tra cking is another important step in
tubulogenesis [77,77,78]. This intracellular tra cking is well known to be regulated by
Rab family proteins such as Rab5, Rab8, and Rab11 via early and recycling endosomal
pathways [79, 80]. After being transported to a luminal domain, these apical proteins
play a role in the later formation of lumen. For example, Ezrin/Radixin/Moesin (ERM)
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interact with AQP-8 [81] in an apical domain to regulate the water-channel activity in
Caenorhabditis elegans.
To elucidate the molecular mechanisms underlying tubulogenesis, several tubulo-
genesis models have been used (Fig. 1.4). The most studied model of tubulogenesis
is the Madin-Darby canine kidney (MDCK) cells [82–86]. MDCK cells demonstrate
cellular functions at molecular levels in detail during tubulogenesis, as was introduced
above. However, little is known about the mechanisms of tubulogenesis proceeding in
an in vivo environment in living animals. Therefore, in vivo model organisms have
recently begun to be used, such as the Caenorhabditis elegans intestine and Drosophila
tracha. In 2009, the Ciona notochord was also reported as a tubulogenesis model and
has since gained attention for such a purpose. The highly trackable and reproducible
behavior of Ciona notochord cells provide us good opportunities to gain insights into
the molecular aspects of in vivo tubulogenesis, which are strictly regulated in terms
of space and time. In future, these models may provide insight into the molecular
mechanisms of in vivo tubulogenesis.
14
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A  3D endothelial cell culture
B  MDCK cell culture
C  Zebrafish vasculature
D  D. melanogaster tracheal fusion cells
E  D. melanogaster tracheal terminal cell
F  C. elegans excretory cell
Figure 1.4. Experimental models of tubulogenesis: (A) 3D endothelial cell cul-
ture, (B) MDCK cell culture, (C) Zebrafish vasculature, (D) Drosophila melanogaster
tracheal fusion cells, (E) Drosophila melanogaster tracheal terminal cell, and (F)
Caenorhabditis elegans excretory cell. Image adapted from [72].
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1.3 The Present Study
Chemical biology can contribute knowledge to both medicine and biology. Consider-
ing the two fields, the author undertook two chemical biological studies using Ciona
robusta in this thesis. As described in chapter 2, the author conducted research that
may be applicable towards medicine. The author used Ciona as a toxicity evaluation
model animal by examining the phenotype during the early development. Several well-
known drugs with known targets were used to assess their toxicity in Ciona, and it
was found that toxicity profiles could be examined and classified by their phenotype.
As described in chapter 3, the author also uncovered the biology of Ciona notochord
tubulogenesis using a chemical genetics approach. UTKO1, an inhibitor of tumor cell
migration, was found to inhibit Ciona notochord tubulogenesis through the phenotypic
screening of chemical compounds from Ciona development. This result prompted the
author to elucidate the molecular mechanisms of this occurrence by identifying the
target protein, 14-3-3"a. Furthermore, UTKO1 made it possible to examine the func-
tion of 14-3-3"a during tubulogenesis. By identifying the binding protein of 14-3-3"a,
ezrin/radixin/moesin (ERM), the author shows the significance of their interaction
during tubulogenesis. Finally, the author concludes these chemical biological studies
using Ciona.
16
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Toxicity evaluation using Ciona robusta
2.1 Introduction
Toxicity evaluation is an important step for development of new drugs. For toxicity
evaluation, in vivo assays using mammalian animals including rats, mouse, monkeys,
or rabbits have been employed to predict toxicity e↵ects on humans. Although these
results o↵er a better prediction than the results of in vitro assay using cultured cells,
they are costly and time-consuming. To circumvent these problems, for example, ze-
brafish (Danio rerio) is increasingly employed as an animal model for in vitro toxicity
evaluation, taking advantage of its low cost, ease of management, rapid development,
and a transparent body convenient for observation [87–91]. Indeed, toxicity evaluation
using zebrafish can provide insights into toxicity information including cardiotoxicity,
hepatotoxicity, and neurotoxicity, which resemble human toxicity profiles [89, 92–94].
However, using zebrafish or other vertebrate animals for toxicity evaluations has eth-
ical and legal limitations due to the exposure of these animals to pain or distress.
Furthermore, toxicity profiles elucidated by zebrafish alone, or by equivalent “a↵ord-
able” invertebrate animals such as the fruit fly, nematode worm, or sea urchin are
usually not su cient to confirm drug toxicity, suggesting the need for a more e↵ective
animal model for drug toxicity evaluation.
Ciona robusta is a chordate invertebrate, the closest living relatives of vertebrates.
Ciona tadpole larvae consist of small numbers of cells and contain a notochord and a
nerve cord as seen in vertebrates [61], and have similar organs as humans including a
heart, stomach, intestine, esophagus, testis, and ovary. In 2002, the whole genome of
Ciona was sequenced [54], and Ciona is now in the midst of mainstream developmental
biology [95]. Embryonic and larval development of Ciona is as rapid as that of the
zebrafish. Adult organs begin to form as early as 2 dpf (days post fertilization) after
metamorphosis [96], and a series of dynamic morphogenetic movements occur, char-
acterized by the degeneration of the tail, removal of larval tunic, and rotation of the
body axis. Transparent body, low husbandry costs, and large numbers of individuals
are also common advantages shared with the zebrafish. Moreover, since Ciona does
not have a pain-related channel [62], and are not vertebrates, they are less restricted
than the zebrafish by ethical and legal issues.
Previously, Ciona have been treated with more than 351 types of drugs (http://d
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x.doi.org/10.1038/npre.2010.5087.1. Available from: Nature Precedings.), suggesting
Ciona is sensitive enough to cause drug-induced e↵ects. In the present study, the
author investigated whether Ciona is useful as a new animal model for drug toxicity. In
particular, the author focused on the phenotypes in Ciona larvae treated with cytotoxic
drugs. By using the toxicity endpoints a↵ected by cytotoxic drugs, the author aimed to
use Ciona not only for assessing the presence of drug toxicity, but also for characterizing
drug toxicity.
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2.2 Result
2.2.1 Setting of developmental indicators in Ciona
From 2 dpf to 4 dpf, adult organs of Ciona begin forming dynamically and larval
organs such as the tail muscle and notochord are degenerated in the process of meta-
morphosis (Fig. 2.1). According to the developmental stage of Ciona after larval stage
(FABA2; http://chordate.bpni.bio.keio.ac.jp/faba2) tail absorption and ampulla elon-
gation initiate from Stage 32 (27 hpf (hours post fertilization)) and Stage 35 (30 hpf),
respectively. Subsequently, body axis rotation occurs during Stages 36-40 (30–57 hpf),
the size of the stomach increases at Stage 38 (3 dpf), and heart beat initiates around
3 dpf, accompanying the remarkable increase in body size of the Ciona. Here, the au-
thor quantified these important developmental events at 2–4 dpf: degenerated tail size,
ampulla length, rotation of the body axis, stomach size, heart rate, and body size. As
shown in Fig. 2.2, quantifying these six events showed remarkable di↵erences between
2 dpf and 4 dpf, confirming their usefulness as developmental indicators in Ciona.
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A B2 dpf 3 dpf 4 dpf
Stage 39Stage 38Stage 37
Body size
Stomach size
Degenerated tail size
Ampulla length
Heart rate
Rotation of body axis
Figure 2.1. Setting of developmental indicators in Ciona: (A) Phenotypes of
Ciona larvae at 2, 3, and 4 dpf. (B) Six developmental indexes of 4 dpf Ciona larvae in
A, including degenerated tail size (yellow), ampulla length (orange), rotation of body
axis (green), stomach size (red), heart rate (purple), and body size (blue).
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Figure 2.2. Quantification of six developmental indicators from 2-4 dpf:
Quantification of developmental indexes of Ciona larvae from 2 hpf to 4 dpf. Degener-
ated tail size, ampulla length, and body size were calculated as fold change relative to
the larvae at 2 hpf. Rotation of body axis was measured using protractor, and heart
rate was measured for 30 seconds. Data were obtained from at least two independent
experiments and averaged (n=10). ND indicates not detected. Error bars are SEM
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2.2.2 E↵ect of rotenone and paclitaxel on developmental in-
dicators
Next, the author assessed the developmental toxicity of cytotoxic drugs in larval Ciona
using the above six developmental indicators. When larval Ciona at 2 dpf were treated
with rotenone known as a mitochondrial respiratory inhibitor, the absorption of the
degenerated tail, elongation of ampulla, heart rate, and body growth were significantly
suppressed dose-dependently at 4 dpf (Fig. 2.3, 2.4). The author next examined the
e↵ect of paclitaxel, a tubulin depolymerization inhibitor, on the developmental indica-
tors. Paclitaxel also inhibited the elongation of ampulla, heart rate, and body growth
as observed in the treatment with rotenone. However, unlike rotenone, paclitaxel did
not inhibit absorption of the degenerated tail and, furthermore, did inhibit the rotation
of body axis (Fig. 2.3, 2.5). These results suggest the developmental indicators the
author chose can be used as “toxicity endpoints” for assessing the presence of drug
toxicity. Furthermore, the inhibition patterns of toxicity endpoints are not the same
among drugs, suggesting that these inhibition patterns are representing drug toxicity
profiles.
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Figure 2.3. E↵ect of rotenone and paclitaxel on divelopmental indicators:
Ciona larvae at 2 dpf were treated with rotenone or paclitaxel, and observed at 4 dpf
by a stereoscopic microscope.
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Figure 2.4. E↵ect of rotenone on developmental indicators: Ciona larvae at
2 dpf were treated with rotenone, and observed at 4 dpf by a stereoscopic microscope.
Degenerated tail size, ampulla length, stomach size, body size were calculated as fold
change relative to control. Data were obtained from at least two independent exper-
iments, and averaged (n=10). Black triangle indicates significant inhibition at MTC.
Error bars are SEM *p<0.01, **p<0.001 compared with control (ctrl), two-tailed t-
tests.
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Figure 2.5. E↵ect of paclitaxel on developmental indicators: Ciona larvae at
2 dpf were treated with paclitaxel and observed at 4 dpf by a stereoscopic microscope.
Degenerated tail size, ampulla length, stomach size, body size were calculated as fold
change relative to control. Data were obtained from at least two independent exper-
iments, and averaged (n=10). Black triangle indicates significant inhibition at MTC.
Error bars are SEM *p<0.01, **p<0.001 compared with control (ctrl), two-tailed t-
tests.
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2.2.3 Comparison of toxicity profiles among targets
The above results promoted the author to examine whether di↵erences in toxicity pro-
files among drugs depend on their targets. The author added antimycin A, oligomycin
A, and MPP+ as mitochondrial respiratory inhibitors, vinblastine as a tubulin poly-
merization inhibitor, and cisplatin and doxorubicin as DNA/RNA synthesis inhibitors
to quantify toxicity endpoints. The author carried out two independent experiments
and obtained highly reproducible data.
The author chose minimum toxic concentration (MTC) in which either toxicity end-
point was significantly a↵ected (p<0.01) (Fig 2.4–2.11) and performed a hierarchical
cluster analysis of toxicity profiles of each drug at MTC. The results are displayed in
the form of a heat map in Fig. 2.12. The heat map employs a gradient color scale from
green, indicating a relatively weak e↵ect, to magenta, indicating a relatively strong
e↵ect, interpolated over yellow, indicating a relatively moderate e↵ect among six tox-
icity endpoints in each drug. The author expected the drugs showing a similar mode
of action to be clustered in the same tree. Indeed, tubulin polymerization/depolymer-
ization inhibitors (paclitaxel and vinblastine), DNA/RNA synthesis inhibitors (dox-
orubicin and cisplatin), and mitochondrial respiratory inhibitors (rotenone, antimycin
A, MPP+, and oligomycin A) were all clustered in the same positions. Moreover, the
characteristic features of toxicity endpoints a↵ected by the drugs in Ciona were clas-
sified into two clusters. One cluster contained rotation of body axis, body growth,
and heart rate; they were relatively sensitive to tubulin polymerization/depolymer-
ization inhibitors, but insensitive to DNA/RNA synthesis inhibitors. Another cluster
contained absorption of degenerated tail, ampulla elongation, and stomach formation;
these were sensitive to DNA/RNA synthesis inhibitors, but relatively insensitive to
tubulin polymerization/depolymerization inhibitors. In addition, tail absorption and
ampulla elongation, but not stomach formation, were strongly suppressed by the mi-
tochondrial respiratory inhibitors.
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Figure 2.6. Quantification of toxicity endpoints for the 4 dpf Ciona larvae
treated with MPP+ at 2 dpf. Data were obtained from at least two independent
experiments and averaged (n=10). Degenerated tail size, ampulla length, stomach size,
and body size were calculated as fold change relative to control. Black triangle indicates
significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001 compared with
control (ctrl), two-tailed t-tests.
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Figure 2.7. Quantification of toxicity endpoints for the 4 dpf Ciona larvae
treated with oligomycin A at 2 dpf. Data were obtained from at least two in-
dependent experiments and averaged (n=10). Degenerated tail size, ampulla length,
stomach size, and body size were calculated as fold change relative to control. Black tri-
angle indicates significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001
compared with control (ctrl), two-tailed t-tests.
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Figure 2.8. Quantification of toxicity endpoints for the 4 dpf Ciona lar-
vae treated with antimycin A at 2 dpf. Data were obtained from at least two
independent experiments and averaged (n=10). Degenerated tail size, ampulla length,
stomach size, and body size were calculated as fold change relative to control. Black tri-
angle indicates significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001
compared with control (ctrl), two-tailed t-tests.
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Figure 2.9. Quantification of toxicity endpoints for the 4 dpf Ciona larvae
treated with vinblastine at 2 dpf. Data were obtained from at least two indepen-
dent experiments and averaged (n=10). Degenerated tail size, ampulla length, stomach
size, and body size were calculated as fold change relative to control. Black triangle
indicates significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001 com-
pared with control (ctrl), two-tailed t-tests.
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Figure 2.10. Quantification of toxicity endpoints for the 4 dpf Ciona lar-
vae treated with doxorubicin at 2 dpf. Data were obtained from at least two
independent experiments and averaged (n=10). Degenerated tail size, ampulla length,
stomach size, and body size were calculated as fold change relative to control. Black tri-
angle indicates significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001
compared with control (ctrl), two-tailed t-tests.
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Figure 2.11. Quantification of toxicity endpoints for the 4 dpf Ciona larvae
treated with cisplatin at 2 dpf. Data were obtained from at least two independent
experiments and averaged (n=10). Degenerated tail size, ampulla length, stomach size,
and body size were calculated as fold change relative to control. Black triangle indicates
significant inhibition at MTC. Error bars are SEM *p<0.01, **p<0.001 compared with
control (ctrl), two-tailed t-tests.
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Figure 2.12. Cluster analysis of the toxicity profile of cytotoxic drugs: Toxic-
ity profiles of drugs (Doxorubicin, cisplatin, paclitaxel, vinblastine, rotenone, antimycin
A, MPP+, oligomycin A) were clustered using the datasets composed by six normal-
ized toxicity endpoints for each drug. Cluster analysis was performed based on the
complete-linkage method using correlation distance. Rows and columns indicate drugs
and toxicity endpoints, respectively. The heat map shows a gradient color scale from
red, indicating relatively strong inhibition, to green, indicating relatively weak inhibi-
tion among toxicity endpoint.
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These results suggest the developmental drug toxicity profiles of six endpoints the
author set depended on the mechanisms of action behind the drugs, allowing the author
to predict the mode of action by the new drugs, or o↵er a way to classify them based
on functional similarities.
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2.3 Discussion
Current reports regarding toxicity evaluation using Ciona embryogenesis [97–99] as-
sess the presence of toxicity based on mortality rate or abnormal developmental rate.
Here, the author demonstrated an evaluation system for drug toxicity that quantifies
the developmental phenotypic changes of Ciona using six toxicity endpoints. These
endpoints enabled the author to assess not only the presence of toxicity but also the
toxicity profiles represented by the inhibitory patterns of six toxicity endpoints. Un-
fortunately, these toxicity profiles cannot be applied directly to the toxicity profiles of
adult humans since most of the organs used in toxicity endpoints except for the stomach
and the heart do not exist in humans, and toxicity evaluation was performed on devel-
oping Ciona larvae, not adults. However, considering the sensitivity of detecting drug
toxicity, employing six toxicity endpoints during embryonic and larval development is
advantageous due to substantial changes in toxicity endpoints with drug treatment over
a wide range, as seen from 2 dpf to 4 dpf. Furthermore, since previous studies show
embryonic and larval fish are more sensitive to cytotoxic drugs than adults [100, 101],
Ciona larvae relative to fish might be more sensitive to toxicity drugs than adults.
Using this toxicity evaluation system, the author detected toxicity in Ciona at
MTC. As shown in Table 2.1, MTCs in Ciona roughly corresponded to concentrations
of each drug similar to toxic e↵ects experienced by zebrafish. Paclitaxel shows no toxic
e↵ect on zebrafish larvae near MTC, but can inhibit cleavage of fertilized eggs in sea
urchin at 10 µM [102]. Nevertheless, MTCs were validated in other species, and toxicity
profiles at MTCs may be caused by su cient inhibition of the targets. At MTCs, the
author obtained a variety of toxicity profiles that were dependent on the drugs, but
also similar toxicity profiles in drugs with similar modes of action. However, it is not
clear how these toxicity profiles are subjected to the mode of action; therefore, future
studies are needed to describe more precisely the inhibitory mechanisms of toxicity
endpoints.
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Table 2.1. Comparative toxicity of drugs employed in this study vs. previous studies
using other species
Drugs This study Literature
MTC Conc. Species Description Ref.
Paclitaxel 3 µM 10 µM Sea urchin Inhibition of cleavage of eggs. [102]
Vinblastine 3 µM 3 µM Zebrafish Lethal e↵ect. [103]
Doxorubicin 30 µM >43 µM Zebrafish Lethal e↵ect. [100]
Cisplatin 30 µM 50 µM Zebrafish Hair cell death. [104]
Rotenone 0.3 µM 0.3 µM Zebrafish Lethal e↵ect. [105]
Antimycin A 10 nM 2.9 nM Zebrafish Lethal e↵ect. [106]
MPP+ 1 µM 1 µM Zebrafish Loss of dopaminergic cells. [105]
Oligomycin A 3 µM 1.23 µM Zebrafish Lethal e↵ect. [105]
In the present study, the author demonstrated the possibility of using Ciona as
a new animal model to evaluate drug toxicity. Toxicity assay using Ciona is also a
promising step toward high-throughput screening: adult Ciona produce a higher egg
yield than zebrafish, allowing assays using thousands of synchronized embryos with
large numbers of drugs. Future studies of toxicity evaluation using Ciona can also
facilitate the development of new drugs, saving time and costs.
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2.4 Materials and Methods
2.4.1 Biological materials and drug treatment
Ciona were cultivated in Maizuru, or Misaki (National Bio-Resource Project) of Japan.
Adults were maintained under constant light to induce oocyte maturation. Eggs and
sperm were obtained by dissecting the gonadal and sperm ducts, respectively, and
cross-fertilization was performed in plastic petri dishes. After fertilization, embryos
were cultured at 18 C until 47 hpf. Of note, at 24 hpf, deformed larvae, or tadpole-
shaped larvae not attached to the bottom of the dish were eliminated from the dish.
After collecting the larvae from the dish, larvae were evenly distributed to a 12-well
plate, with each well containing about a hundred larvae suspended in 1 ml of sea water,
folowed by an addition of 10 µl of drug at 48 hpf.
2.4.2 Drugs
The author chose the following drugs commonly known to induce cytotoxic e↵ects in
various species through known modes of action: rotenone (Sigma, St. Louis, USA), an-
timycin A (BioVision, Mountain View, USA), oligomycin A (Cayman Chemical, Michi-
gan, USA), MPP+ (1-methyl-4-phenylpyridinium) (Sigma, St. Louis, USA) known as
mitochondria respiratory inhibitor, paclitaxel (Wako Pure Chemical, Osaka, Japan),
vinblastine (Wako Pure Chemical) known as tubulin polymerization/depolymeriza-
tion inhibitor, cisplatin (Wako Pure Chemical), and doxorubicin (Sigma) known as
DNA/RNA synthesis inhibitor.
2.4.3 Quantification
Pictures of larvae were taken using a microscopy camera (WRAYCAM-SR300, WR
AYMER, Osaka, Japan) attached to a stereoscopic microscope (OLYMPUS, SZX16,
Tokyo, Japan), with a zoom ratio of 8:1. Pictures were used for quantifying the size
of the degenerated tail, stomach, and body, and the length of ampulla using ImageJ
software. The angle of the body axis was measured by protractor. Heart rate was
measured for 30 seconds.
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2.4.4 Hierarchical Cluster Analysis
First, each dataset for toxicity endpoints was normalized by z-score using all the con-
centrations of eight drugs. Next, these normalized datasets for toxicity endpoints were
analyzed by cluster analysis to examine the relevance among toxicity endpoints. Then,
normalized data were aligned with the relevance of toxicity endpoints in each drug
using further cluster analysis to examine the relevance among the toxicity profiles of
drugs. Cluster analysis of toxicity endpoints and toxicity profiles of drugs was done by
complete linkage based on correlation distance, using R version 3.1.1 (http://www.R-
project.org).
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3.1 Introduction
Biological tubes serve as fundamental structural units in a diverse set of organs, includ-
ing lung, liver, gut, and kidney, playing roles in both the exchange of biological materi-
als and structural support. Tubulogenesis involves changes in cell shape [81,107–110],
vesicle tra cking [74, 85, 111–114], and luminogenesis [86, 115–117]. Understanding
how these changes occur and how they are coordinated in space and time is essen-
tial for understanding tubulogenesis during normal development, and is also becoming
increasingly important for regenerative medicine.
The notochord of Ciona robusta provides a simple in vivo model for tubulogene-
sis. The ascidian notochord initially comprises a single stack of 40 post-mitotic cells
that form the core of the tadpole tail. As the notochord begins to elongate along
its anterior/posterior (A/P) axis [118–120], extracellular lumen pockets emerge be-
tween adjacent cells, expand, and fuse with each other to form a single central lu-
men [121–123]. Although this process has been extensively characterized, the under-
lying mechanisms remain poorly understood. Recent studies have revealed molecules
that are associated with both notochord elongation and tubulogenesis. For example,
cell elongation is facilitated by actomyosin networks (complexes of actin and myosin
II) localizing in the basal contractile ring, together with other components such as
 -actinin and cofilin [122, 124]. Lumen formation requires the establishment of polar-
ity by Par3/Par6/aPKC [125] and the cytoskeletal crosslinker Ezrin/Radixin/Moesin
(ERM) [122], both of which play roles in other tubulogenesis processes, including
those occurring in MDCK cells [74,83,126], the Drosophila trachea [109,114], and the
Caenorhabditis elegans intestine [115, 127]. However, it remains largely unknown how
these molecules work together, or how cell elongation and lumen formation combine,
suggesting there are novel mediators that a↵ect these genes.
One of the best approaches for elucidating the molecular mechanisms underlying
biological processes is a chemical genetics approach utilizing chemical inhibitors. The
compounds identified from phenotypic screening have previously led us to identify un-
expected molecules responsible for various phenotypes. Furthermore, such compounds
enable us to examine the functional role of the target molecule just by changing their
treatment time or concentration. This chemical genetics strategy has been useful not
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only to in vitro cell biology [1, 13], but also to in vivo developmental biology [94, 128].
Here, the author demonstrates an in vivo chemical biological approach to identify
molecules responsible for tubulogenesis and to elucidate their functional roles in vivo.
The author identifies a chemical inhibitor of tubulogenesis in Ciona robusta. The
author identifies its target protein 14-3-3"a, and shows 14-3-3"a interacts with ERM
during lumen formation to control dynamic cycles of basal accumulation and directed
transport of 14-3-3"a, ERM, myosin II and other factors from the basal cortex to
the lumen-facing apical domain, and to promote lumen formation and growth during
tubulogenesis.
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3.2 Result
3.2.1 Ciona morphogenesis inhibitor screening
To identify compounds that modulate the morphogenesis of Ciona robusta, phenotypic
screening was conducted. Embryos of Ciona reach the tailbud stage at 12 hpf and
become swimming larvae at 21 hpf, at which point they possess their maximum tail
length [61]. Ciona embryos at 12 hpf were treated with compounds from in-house
chemical library and assessed their e↵ects on subsequent development. Most of the
compounds showed toxicity in Ciona, where malformation of trunk, otolith, ocellus,
and the tail were observed (Fig. 3.1).
Xanthohumol LY294002
Bafilomycin Leptomycin SB415286
Oligomycin
Control 
1 μM 10 μM 3 μM
10 nM 10 nM 10 nM
Figure 3.1. Examples of the phenotypes of Ciona at 21 hpf treated with
various compounds: Ciona larvae at 12 hpf were treated with control (MeOH), xan-
thohumol (1µM), LY294002 (10 µM), oligomycin (3 µM), bafilomycin (10 nM), lepto-
mycin (10 nM), and SB415286 (10 nM), and were observed under optical microscope.
Yellow arrowheads indicate otolith/ocellus. Scale bars indicate 200 µm.
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Here, UTKO1 (Fig. 3.2), a tumor cell migration inhibitor which was developed
previously [129, 130], was found to inhibit tail elongation in a dose-dependent manner
(Fig. 3.3, A and B). Interestingly, UTKO1 did not appear to cause any noticeable
morphological defects in other body parts, such as the trunk (Fig. 3.3, C), or defects
in other developmental processes such as ocellus melanization (Fig. 3.3, D), although
it did cause defects in papillae formation and locomotion (Fig. 3.3, E).
OH
HO
OH
CHO
cis
114
Figure 3.2. Structure of UTKO1: UTKO1 is a series of moverastin derivatives
and was synthesized by Prof. Watanebe of University of Tokyo.
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Figure 3.3. E↵ects of UTKO1 on Ciona development: (A) Picture of Ciona
larvae at 21 hpf, treated with UTKO1 from 12 hpf. (B, C) Quantification of tail length
(B) and trunk ellipticity (defined as the short [dorsal/ventral] axis divided by the long
[anterior/posterior] axis) (C) of larvae treated with UTKO1. The data are presented
as mean ± SD (n = 25 for each condition; ** P <0.05; *** P <0.001; Dunnett’s test;
each compared with the control at the same time point). (D) Phenotypes of the Ciona
trunk region at 15 hpf after treatment with UTKO1 (10 µM) from 12 hpf. Yellow
arrows indicate the ocellus melanization. (E) Phenotypes of the Ciona trunk region at
21 hpf after treatment with UTKO1 (10 µM) from 12 hpf. Yellow arrows indicate the
adhesive papillae.
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3.2.2 UTKO1 inhibits Ciona notochord tubulogenesis
The tail-selective phenotype resulting from UTKO1 treatment prompted us to look
more closely at the dynamics of notochord elongation and tubulogenesis in UTKO1-
treated embryos. Notochord elongation and tubulogenesis involves four distinct devel-
opmental phases (Fig. 3.4): I) Completion of notochord cell alignment into a single file
and elongation of notochord cells along the AP axis; II) opening of small extracellular
lumen pockets between adjacent notochord cells; III) expansion of the lumen pockets,
accompanied by crawling movements of the notochord cells; and IV) connection of
the lumen pockets to form a single lumen at the center of the notochord tube [107].
Treatment with UTKO1 caused a concentration-dependent delay in the opening and
expansion of the lumen, relative to untreated controls (Fig. 3.4 and Fig. 3.5). How-
ever, this inhibitory e↵ect of UTKO1 was not observed when it was added at 16 hpf
(Fig. 3.6), suggesting that UTKO1 selectively inhibits phase I and II, which occur from
12–16 hpf. Thus, UTKO1 was found to inhibit lumen formation in Ciona notochord
during the early stages of tubulogenesis.
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Figure 3.4. UTKO1 inhibits lumen formation in the Ciona notochord (1):
Schematic illustrations and confocal images of Ciona tails treated with or without
UTKO1 during notochord tubulogenesis. Notochord cells are colored red, and the
lumens are blue. Confocal images were obtained by staining F-actin with phalloidin
Alexa 488. Abbreviations: A, anterior; D, dorsal; P, posterior; V, ventral. Scale bars:
10 µm.
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Figure 3.5. UTKO1 inhibits lumen formation in the Ciona notochord (2):
Quantification of lumen ratio in the larvae treated with UTKO1. Lumen ratio was
calculated by dividing lumen area by whole notochord cell area. Data presented as
mean ± SD (n = 4-5 for each condition; *** P <0.001; Dunnett’s test, each compared
with control at the same time point).
UTKO1 (3  μM)
Control 12 hpf 16 hpf Treatment 
from
Figure 3.6. Change of UTKO1 treatment period: UTKO1 does not inhibit the
lumen formation when added from 16 hpf. Confocal images were obtained by staining
F-actin with phalloidin Alexa 488. Scale bars: 10 µm.
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3.2.3 Structure-Activity Relationship analysis using UTKO1
analogues
To identify the moiety of UTKO1 required for its inhibitory activity, the author per-
formed a structure-activity relationship (SAR) analysis using UTKO1 analogues that
had been previously synthesized [129]. Analogues that lacked the hydroxyl group
present at C-11 of UTKO1 (UTKO9, UTKO10, UTKO13, UTKO14, and UTKO16),
or the methylene group at C-4 (UTKO7), did not inhibit tubulogenesis, suggesting
that these two groups are critical for inhibitory activity (Fig. 3.7, 3.8). In contrast, an
analogue that lacks the aldehyde group (UTKO12) and four stereoisomers of UTKO1,
retained inhibitory activity (Fig. 3.7–3.10), indicating that the aldehyde group and a
specific three-dimensional shape are not required to inhibit tubulogenesis.
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Figure 3.7. Structure–activity relationship of UTKO1 analogues (1): E↵ect
of UTKO1 analogues on Ciona notochord tubulogenesis at 21 hpf. Treatment with
these compounds commenced from 12 hpf, and the phenotype resulting from each was
observed using confocal images stained with phalloidin Alexa 488 for F-actin. Red
circles indicate the alterations to UTKO1. Scale bars: 10 µm.
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Figure 3.8. Structure–activity relationship of UTKO1 analogues (2): Quan-
tification of the lumen ratio in larvae treated with UTKO1 analogues. The data are
presented as mean ± SD (n = 3 for each condition; ** P <0.05; *** P <0.001; Dun-
nett’s test, each compared with the control.
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Figure 3.9. E↵ect of UTKO1 isomers on Ciona notochord tubulogenesis (1):
E↵ect of UTKO1 analogues on Ciona notochord tubulogenesis at 21 hpf. Treatment
with these compounds commenced from 12 hpf, and the phenotype resulting from each
was observed using confocal images stained with phalloidin Alexa 488 for F-actin.
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Figure 3.10. E↵ect of UTKO1 isomers on Ciona notochord tubulogenesis
(2): Quantification of the lumen ratio in larvae treated with UTKO1 analogues (1:
control; 2: (2’R,1”’S,6”’S)-UTKO1; 3: (2’S,1”’S,6”’S)-UTKO1; 4: (2’S,1”’R,6”’R)-
UTKO1; 5:(2’R,1”’R,6”’R)-UTKO1;). The data are presented as mean ± SD (n = 3
for each condition; ** P <0.05; *** P <0.001; Dunnett’s test, each compared with the
control.
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3.2.4 14-3-3"a is a direct target of UTKO1 in Ciona
Based on these results, the author used a UTKO1 analogue in which the aldehyde
group is replaced by biotin (B-UTKO1ox; Fig. 3.11), to identify target proteins in
Ciona lysates that bind UTKO1.
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Figure 3.11. Structure of two biotinylated versions of UTKO1: B-UTKO1ph
and B-UTKO1ox: B-UTKO1ph is a UTKO1 analogue in which the hydroxyl group
present at C-11 of UTKO1 is replaced by biotin. B-UTKO1ox is a UTKO1 analogue
in which the aldehyde groups is replaced by biotin.
Previously, UTKO1 had been shown to target human 14-3-3⇣ protein [130], an
adapter protein that binds to diverse client proteins [131, 132]. Therefore, the author
used the human anti-14-3-3 antibody as a probe for the UTKO1 target proteins in Ciona
robusta. Proteins that bind to the human anti-14-3-3 antibody were pulled down from
the Ciona lysate by B-UTKO1ox (Fig. 3.12), suggesting that UTKO1 targets one or
more of the four isoforms of Ciona 14-3-3: "a, "b,  1, and/or  2.
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Figure 3.12. B-UTKO1ox binds to Ciona 14-3-3 protein: Ciona lysate was
incubated with biotin (1 nmol) or B-UTKO1ox (1 nmol), precipitated with avidin
beads, and subjected to SDS-PAGE. Ciona 14-3-3 protein was detected using human
anti-14-3-3 antibody.
To identify the specific target(s), the author prepared each 14-3-3 isoform as a
recombinant protein fused to glutathione S-transferase (GST), and tested for direct
binding to B-UTKO1ox. As shown in Fig. 3.13, among the four Ciona 14-3-3 isoforms,
only 14-3-3"a was strongly pulled down by B-UTKO1ox, and biotin-free UTKO1 in-
hibited the interaction (Fig. 3.14). Conversely, a UTKO1 analogue that lacked the
C-11 hydroxyl group (UTKO10) did not show the same pattern (Fig. 3.14).
Avidin beads pull down
GST-14-3-3 
B-UTKO1ox
Biotin
input
εa εb γ1 γ2
anti-α-GST
Figure 3.13. B-UTKO1ox binds selectively to Ciona 14-3-3"a (1): Purified
GST-tagged 14-3-3 isoforms were incubated with B-UTKO1ox or biotin, precipitated
with avidin beads, and subjected to SDS-PAGE. Proteins were blotted with anti-GST
antibody.
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Figure 3.14. B-UTKO1ox binds selectively to Ciona 14-3-3"a (2): GST-14-
3-3"a was incubated with UTKO1 or UTKO10 prior to precipitation with biotin or
B-UTKO1ox, using avidin beads. The precipitated proteins were subjected to SDS-
PAGE. Proteins were blotted with anti-GST antibody.
Unlike B-UTKO1ox, B-UTKO1ph did not strongly pull-down GST-14-3-3"a (Fig.
3.15). These results suggest that UTKO1 binds directly and selectively to 14-3-3"a
via the hydroxyl group at C-11, which is important for its inhibitory activity against
tubulogenesis. This selective binding of UTKO1 to 14-3-3"a allowed us to explore the
functional role of 14-3-3"a in lumen formation during Ciona tubulogenesis.
Biotin
B-UTKO1
ox ph
anti-α-GSTGST-14-3-3εa
Figure 3.15. B-UTKO1ox binds selectively to Ciona 14-3-3"a (3): Purified
GST-tagged 14-3-3 isoforms were incubated with biotin, B-UTKO1ox, or B-UTKO1ph,
precipitated with avidin beads, and subjected to SDS-PAGE. Proteins were blotted
with anti-GST antibody.
54
3.2 Result
3.2.5 14-3-3"a is required for notochord tubulogenesis
14-3-3"a mRNA was highly expressed during notochord tubulogenesis and peaked at
15 hpf (Fig. 3.16). To investigate the role of 14-3-3"a, the author injected a morpholino
anti-sense oligo nucleotide (MO) directed against 14-3-3"a into fertilized eggs, to inhibit
the synthesis of 14-3-3"a protein, starting from the fertilized egg stage. Treatment with
14-3-3"a MO caused a tail elongation defect that could be detected as early as 12 hpf,
and increased in severity as development progressed, up until 21 hpf (Fig. 3.17, A and
B). At 21 hpf, larvae treated with 14-3-3"a MO exhibited a failure of lumen opening
or expansion, as seen with UTKO1 treatment (Fig. 3.18, A–C). On the other hand,
14-3-3"a MO also caused defects in trunk development (Fig. 3.17, C), consistent with
the 14-3-3"a expression pattern in the trunk [133,134] (Fig. 3.26). The tail defects, but
not trunk defects, were rescued by the notochord-specific expression of MO-resistant
14-3-3"a, driven by a notochord-specific brachyury promoter (Fig. 3.17, A–B, Fig.
3.18, D, and Fig. 3.19), confirming that UTKO1 inhibits notochord lumen formation
by binding to 14-3-3"a.
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Figure 3.16. Expression of 14-3-3"a: Time course of 14-3-3"a mRNA expression
from fertilization to the end of notochord tubulogenesis. 14-3-3"a mRNA expression
was normalized by GAPDH.
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Figure 3.17. Phenotype of Ciona larvae treated with 14-3-3"a Morpholino
Oligo: (A) Ciona larvae at 21 hpf injected with Control MO, 14-3-3"a MO, and 14-3-
3"a MO + Bra>14-3-3"a:EGFP. (B, C) Quantification of the length of the tail (B) and
trunk ellipticity (C) of larvae treated with Control MO, 14-3-3"a MO, and 14-3-3"a
MO + Bra>14-3-3"a:EGFP. Scale bars: 200 µm (A).
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Figure 3.18. 14-3-3"a is required for lumen formation in the Ciona noto-
chord (1): (A–D) Confocal images of Ciona larvae at 21 hpf injected with Control
MO (A), 14-3-3"a MO (B–C), and 14-3-3"a MO + Bra>14-3-3"a:EGFP (D). Con-
focal images of F-actin stained by Alexa 488 phalloidin (green) (A–C) or Alexa 594
phalloidin (red) (D). In (D), GFP-14-3-3"a was further stained with anti-GFP (green).
Scale bars: 10 µm
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Figure 3.19. 14-3-3"a is required for lumen formation in the Ciona no-
tochord (2): Quantification of the lumen ratio treated with control MO (color 1),
14-3-3"a MO (color 2), and 14-3-3"a MO + Bra>14-3-3"a:EGFP (color 3). The data
are presented as mean ± SD (*** P <0.001; Bonferroni multiple comparison test).
3.2.6 14-3-3"a interacts directly with ezrin/radixin/moesin
The author hypothesized that UTKO1 exerts its inhibitory e↵ects by preventing 14-
3-3"a from binding to one or more client proteins responsible for notochord lumen
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formation. Since UTKO1 showed greater selectivity toward notochord cells (Fig. 3.3,
B, C) relative to 14-3-3"a MO treatment (Fig. 3.17, B, C), the author focused on
potential clients that are predominantly expressed in notochord cells during tubuloge-
nesis [135, 136]. Of these, ezrin/radixin/moesin (ERM) is the most likely candidate,
since it is required for lumen formation during Ciona notochord development [122],
as well as in other tubulogenesis processes [74], and was recently reported to interact
directly with the 14-3-3 protein in human cell lines to regulate cell migration [137].
Indeed, ERM protein purified from E. coli bound 14-3-3 protein from Ciona lysate,
detected by anti-14-3-3 (Fig. 3.20) and also bound 14-3-3"a purified from E. coli (Fig.
3.21), supporting a direct interaction between 14-3-3"a and ERM in Ciona.
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Figure 3.20. 14-3-3"a interacts with ERM in Ciona lysate: His-tagged ERM
was purified from E. coli and mixed with Ciona lysate. His–ERM-binding proteins
were captured using Ni-beads, eluted by imidazole, and subjected to SDS-PAGE.
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Figure 3.21. 14-3-3"a interacts directly with ERM: Purified His-tagged ERM
protein was preincubated with or without UTKO1 (A)/UTKO10 (B), mixed with
GST/GST14-3-3"a, precipitated by GSH beads, and subjected to SDS-PAGE.
Furthermore, the interaction between 14-3-3"a and ERM was inhibited in a dose-
dependent manner by UTKO1 (Fig. 3.21, A), but not by an o↵-targeted derivative,
UTKO10 (Fig. 3.21, B). Deletion mutants of 14-3-3"a lacking amino acids 156–206
did not bind to B-UTKO1ox (Fig. 3.22) or ERM (Fig. 3.23), indicating that ERM
and UTKO1 bind to the same 156–206-aa domain. This domain corresponds to the
Ezrin binding domain in human 14-3-3⇣ [137], suggesting the existence of a conserved
interaction across species. Together, these results implicate ERM as a 14-3-3"a client
protein that mediates the e↵ects of 14-3-3"a on notochord tubulogenesis.
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Figure 3.22. UTKO1 Binding region in 14-3-3"a: (A) Schematic illustrations
of deletion mutants of 14-3-3"a purified from the E. coli BL21 strain. (B) Deletion
mutants of GST-14-3-3"a were incubated with B-UTKO1ox or biotin, precipitated by
avidin beads, and subjected to SDS-PAGE.
GSH pull down
W
T
Δ
C5
0
Δ
C1
00
C1
00
C5
0
C5
0-
10
0
GS
T
anti-α-GST
anti-His
His-
ERM
deletion
mutants
Figure 3.23. ERM Binding region in 14-3-3"a: Purified His-tagged ERM pro-
tein was mixed with GST-14-3-3 deletion mutants, precipitated by GSH beads, and
subjected to SDS-PAGE.
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3.2.7 Colocalization of 14-3-3"a and ERM in the basal con-
tractile ring
Immunostaining using specific antibodies (Fig. 3.24, A, B) revealed that 14-3-3"a was
ubiquitously expressed in various cell types, including notochord, epidermis, muscle,
and neuronal cells (Fig. 3.25 and Fig. 3.26). On the other hand, ERM was almost
exclusively expressed in the notochord, with lower levels in the neural tube and in some
neuronal cells in the trunk region.
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Figure 3.24. 14-3-3"a antibody: (A) Specificity of anti-14-3-3"a against 14-3-3"a
protein purified from E. coli. Four isoforms of 14-3-3 proteins fused with an MBP tag
were adjusted to the same amount, subjected to SDS-PAGE, and blotted with anti-14-
3-3"a and anti-MBP antibodies. (B) Ciona lysate at 15 hpf treated with or without
UTKO1 from 12 hpf were subjected to SDS-PAGE and blotted with anti-14-3-3"a
antibody. Tubulin is a loading control.
61
Chapter 3
Chemical genetics reveals the molecular mechanisms of Ciona tubulogenesis
A
anti-14-3-3εa anti-ERM Merge
B anti-ERM Mergeanti-14-3-3εa
Figure 3.25. Expression of 14-3-3"a and ERM: (A) Immunohistochemistry of
the 14-3-3"a and ERM proteins in the trunk, using their respective antibodies, at 21
hpf. (B) Immunohistochemistry of the 14-3-3"a (green) and ERM (red) proteins in the
tail, using their respective antibodies, at 18 hpf. Scale bars: 20 µm (A); 10 µm (B).
Focusing on notochord cells, 14-3-3"a and ERM were strongly colocalized in the
basal contractile ring, an actomyosin-based contractile ring that forms on the basal
surface of notochord cells during notochord elongation and lumen opening at 15 hpf
(Fig. 3.26, arrowheads). In larvae treated with UTKO1, ERM was still localized in the
basal contractile ring, but co-enrichment of 14-3-3"a at the same location was greatly
reduced (Fig. 3.26). Since UTKO1 did not a↵ect the amount of 14-3-3"a protein
expression (Fig. 3.24, B), the disappearance of 14-3-3"a from the basal contractile ring
in notochord cells reflects its delocalization due to loss of binding to ERM. The author
conclude that UTKO1 inhibits the colocalization of 14-3-3"a with ERM in the basal
contractile ring, by inhibiting their direct interaction in the notochord.
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Figure 3.26. Colocalizations between 14-3-3"a and ERM in notochord: Con-
focal images of the immunostaining of 14-3-3"a (green), ERM (red), and the merged
image at 15 hpf in the control and UTKO1 (10 µM)-treated larvae. White arrowheads
indicate the accumulation of 14-3-3"a in the basal contractile ring.
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Figure 3.27. Colocalizations between 14-3-3"a and ERM: Colocalizations be-
tween 14-3-3"a and ERM, expressed as Pearson’s coe cients, measured for the basal
contractile rings. Data presented as mean ± SD (n = 31, 21, and 18 for UTKO1 0
µM, 3 µM, and 10 µM, respectively; ** P <0.05; *** P <0.001; Bonferroni multiple
comparison test.
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3.2.8 14-3-3"a and ERM undergo cycles of basal accumulation
followed by basal-apical transport
To investigate how the colocalization of 14-3-3"a and ERM in the basal contractile
ring is related to lumen formation, the author performed live imaging of each protein
fused with a fluorescent protein under a brachyury promoter. Just before phase II
(the lumen opening, see Fig. 3.4) at 15 hpf, the author observed co-accumulation of
14-3-3"a and ERM in the basal contractile ring (Fig. 3.28), consistent with the results
of immunostaining (Fig. 3.26).
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Figure 3.28. Accumulation of 14-3-3"a in the basal contractile ring: (A–B)
Live imaging of 14-3-3"a:EGFP and mCherry:ERM was performed in notochord cells
using brachyury promoter, just before phase II (15 hpf). The intensities in region of
interest (ROI)(shown in green) were quantified, normalized along the AP axis, and
displayed as a kymograph. The total intensities of all ROIs and time points were
plotted along the relative position of the AP axis. The yellow arrowhead indicates the
accumulation of 14-3-3"a:EGFP in the basal contractile ring; the middle position of
the basal domain.
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During phase II (15-17 hpf), a new behavior emerged in which 14-3-3"a and ERM
periodically appeared and then disappeared from the basal contractile ring (Fig. 3.29,
3.30).
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Figure 3.29. Dynamics of 14-3-3"a and ERM: (A–B) Live imaging of 14-3-
3"a:EGFP and mCherry:ERM was performed in notochord cells using brachyury pro-
moter during phase II (15-17 hpf). White arrowheads indicate the basal contractile
ring.
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Figure 3.30. Kymograph analysis of the dynamics of 14-3-3"a in a WT
embryo: Kymograph analysis of the dynamics of 14-3-3"a during phase II (15–17 hpf)
in a WT embryo. The placement of the cross-sections used to generate the kymograph
is indicated by yellow bands. Yellow triangles indicate the pulsed accumulation of
14-3-3"a. Scale bar: 10 µm.
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To test whether the disappearance of 14-3-3"a and ERM from the basal cortex
during each cycle is associated with their accumulation elsewhere, the author used
spatiotemporal cross-correlation analysis to identify other cellular regions that show
increases in 14-3-3"a or ERM signal intensity that correlate with the disappearance
from the basal cortex. Significantly, the author found that increases in 14-3-3"a and
ERM signal intensities in the apical domain were highly correlated with decreases in
the basal domain during each cycle, with a consistent peak time lag (Fig. 3.31–3.32;
0.8-1.2 min). This suggests that 14-3-3"a and ERM are translocated from the basal
to apical domain during each cycle. Indeed, immunostaining of 14-3-3"a and ERM at
18 hpf, 3 hours after the initiation of phase II, revealed strong apical enrichment (Fig.
3.25, B).
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Figure 3.31. Cross-correlation analysis between the signal of the basal con-
tractile ring and apical domain in a WT larva (Data for each cycle): The
cross-correlation function was calculated for 3 cycles individually for 14-3-3"a (left)
and ERM (right).
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Figure 3.32. Cross-correlation analysis between the signal of the basal con-
tractile ring and apical domain in a WT larva (Averaged data): The averages
of the cross-correlation function in Fig. 3.31 were plotted, with shading representing
the SD. The blue arrowhead indicates the peak, the shift of which indicates a high
correlation between the basal contractile ring and the apical domain.
By live imaging, the author could also detect rapid movements of vesicles containing
14-3-3"a and ERM into the apical domain following their disappearance from the basal
cortex, sometimes accompanied by visible changes in lumen architecture and size (Fig.
3.33). Interestingly, this translocation of 14-3-3"a and ERM was accompanied by the
basal-to-apical movement of cytoplasmic elements, visualized using DIC optics (Fig.
3.34), suggesting that a bulk cytoplasmic flow may carry 14-3-3"a and ERM from the
basal contractile ring to the apical domain.
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Figure 3.33. Translocation of 14-3-3"a and ERM towards the apical do-
main, a↵ecting lumen architecture: (A) Live imaging of 14-3-3"a:EGFP and
mCherry:ERM during their apical translocation. White arrowheads indicate the basal
contractile ring and white arrows indicate the internalizing of 14-3-3"a or ERM toward
the apical domain. (B) Quantification of the signal intensity of 14-3-3"a and ERM in
the basal contractile ring, and the size of lumen over time.
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Figure 3.34. Directed flow of cytoplasm from the basal contractile ring
towards the apical domain: DIC images during lumen formation. Blue dotted lines
indicate the lumen area, red dotted lines indicate inflation of the cytoplasmic region
containing basal factors, and red triangles show the region rushing into the apical
domain.
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3.2.9 Interaction between 14-3-3"a and ERM is required for
their pulsatile accumulation and basal-apical transloca-
tion
In larvae treated with high doses (10 µM) of UTKO1, the pulsatile accumulations of
14-3-3"a and ERM were abolished (Fig. 3.35, 3.36), and the author could no longer de-
tect obvious directed basal-apical movements of 14-3-3"a, ERM, or other cytoplasmic
elements or significant correlations between the apical and basal intensities of 14-3-3"a
and ERM (Fig. 3.38, 3.39). At intermediate doses of UTKO1 (3 µM), pulsatile accu-
mulations of 14-3-3"a and ERM persisted, but the time between pulses was increased
relative to untreated controls (Fig. 3.37). Supporting these live imaging results, treat-
ment with UTKO1 also inhibited the apical accumulation of ERM at 18 hpf in fixed
immunostained embryos (Fig. 3.40).
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Figure 3.35. UTKO1 inhibited the periodical accumulation of 14-3-3"a
and ERM in the basal contractile ring: Live imaging of 14-3-3"a:EGFP and
mCherry:ERM was performed in notochord cells using brachyury promoter (at 15–17
hpf). The larvae were treated with UKTO1. Scale bars: 5 µm.
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Figure 3.36. Kymograph analysis of the dynamics of 14-3-3"a in a UTKO1-
treated embryo: The placement of the cross-sections used to generate the kymograph
is indicated by yellow bands. Scale bar: 10 µm.
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Figure 3.37. UTKO1 inhibits the pulsatile accumulation of 14-3-3"a and
ERM in the basal contractile ring: (A-C) The intensity of 14-3-3"a and ERM in
the basal contractile ring over time during phase II (15–17 hpf) in the larva treated with
control (A), UTKO1 3 µM (B), and UTKO 10 µM (C). Yellow arrowheads indicate
the pulsatile accumulation of 14-3-3"a and ERM. (D) The pulse period of 14-3-3"a
in the basal contractile ring during phase II calculated in the control and UTKO1 3
µM-treated larva. Data are presented as mean ± SD (9 cycles for 3 cells for control,
and 7 cycles for 4 cells for UTKO1 3 µM; *** P <0.001; two-tailed t-test). In UTKO
1 10 µM, pulses were not observed.
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Figure 3.38. Cross-correlation analysis between the signal of the basal con-
tractile ring and apical domain in a UTKO1-treated larva (Data for each
cycle): The cross-correlation function was calculated for 3 cycles individually for 14-
3-3"a (left) and ERM (right).
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Figure 3.39. Cross-correlation analysis between the signal of the basal con-
tractile ring and apical domain in a UTKO1-treated larva (Averaged data):
The averages of the cross-correlation function in Fig. 3.38 were plotted, with shading
representing the SD.
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Figure 3.40. ERM translocation to the apical domain is inhibited by
UTKO1: Immunohistochemical staining of ERM proteins in the tail regions at 18
hpf, treated with or without UTKO1.
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Figure 3.41. Quantification of apical translocation of ERM: Relative intensities
of anti-ERM staining in the apical domain in Fig. 3.40. The ratio was calculated by
dividing the apical anti-ERM intensity by the whole of the anti-ERM intensity in the
notochord. The data are presented as mean ± SD (n = 4–6 for each condition; ** P
<0.05; *** P <0.001; Bonferroni multiple comparison test).
73
Chapter 3
Chemical genetics reveals the molecular mechanisms of Ciona tubulogenesis
These results suggest that an interaction between 14-3-3"a and ERM is required for
their pulsatile accumulation and basal-apical translocation. To test this further, the
author first examined localization of 14-3-3"a in ERM KD embryos, and ERM in 14-
3-3"a KD embryos, focusing initially at 15 hpf, when lumen opening is about to begin
in the wild type. ERM localized normally to the basal contractile ring in 14-3-3"a KD
embryos (Fig. 3.42, A), while 14-3-3"a failed to target the basal contractile ring in
ERM KD embryos (Fig. 3.42, B). A truncated form of 14-3-3"a (14-3-3"a C50-100),
that cannot interact with ERM, also failed to localize to the basal contractile ring when
expressed in place of endogenous 14-3-3"a (Fig. 3.43). Thus, 14-3-3"a is not required
for accumulation of ERM in the basal contractile ring, while the accumulation of 14-
3-3"a in the basal contractile ring depends on its ability to interact with ERM. These
results are consistent with the diminished accumulation of 14-3-3"a, but not ERM, in
the basal contractile ring with UTKO1 treatment (Fig. 3.26).
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Figure 3.42. Kymographs for the live images of 14-3-3"a or ERM in the
basal contractile ring in mutants where the 14-3-3"a–ERM interaction is
inhibited (1): (A–B) Kymographs for the live images of mCherry:ERM in a 14-3-3"a
KD larva (A), 14-3-3"a:EGFP in a ERM KD larva (B) larva at 15 hpf. The intensities
in the ROI (shown in green rectangles) were quantified, normalized along the AP axis,
and displayed as a kymograph. The total intensities of all ROIs and time points were
plotted along relative position of the AP axis.
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Figure 3.43. Kymographs for the live images of 14-3-3"a or ERM in the
basal contractile ring in mutants where the 14-3-3"a–ERM interaction is
inhibited (2): Kymographs for the live images of 14-3-3"a C50-100:EGFP in a 14-
3-3"a KD larva at 15 hpf. The intensities in the ROI (shown in green rectangles) were
quantified, normalized along the AP axis, and displayed as a kymograph. The total
intensities of all ROIs and time points were plotted along relative position of the AP
axis.
The author next examined pulsatile accumulation and translocation of 14-3-3"a
or ERM during phase II (15–17 hpf) in ERM KD, 14-3-3"a KD, and 14-3-3"a C50-
100-expressing embryos. The author found that pulsatile accumulation of 14-3-3"a
(or 14-3-3"a C50-100) in the basal contractile ring was abolished in ERM KD or 14-
3-3"a C50-100-expressing embryos. Conversely, pulsatile accumulation of ERM was
abolished in 14-3-3"a KD embryos. Under all three perturbations, basal-apical flows of
cytoplasm observed by DIC were severely attenuated, correlations between basal and
apical accumulations of either 14-3-3"a or ERM were severely attenuated, and lumens
failed to form and grow (Control: Fig. 3.44, A, C; 14-3-3"a KD: Fig. 3.44, B, D; ERM
KD: Fig. 3.45, A, C; 14-3-3"a C50-100: Fig. 3.45, B, D). These results suggest that
local interactions between 14-3-3"a and ERM at the basal cortex are required for their
pulsatile basal accumulation, directed transport towards the apical/luminal domain,
and lumen formation and growth.
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Figure 3.44. Pulsatile accumulation in the basal contractile ring and api-
cal translocation in the mutant where the 14-3-3"a–ERM interactions are
inhibited. (1): (A, B) The basal ring intensity over time during phase II (15–17
hpf). (A) Larva injected with control MO; (B) larva injected with 14-3-3"a MO; Yel-
low arrowheads indicate their pulsatile accumulation in the basal contractile ring. (C,
D) The cross-correlation analysis between the intensities of the basal contractile ring
and the apical domain. (C) Larva injected with control MO; (D) larva injected with
14-3-3"a MO; The blue arrowhead indicates the peak, the shift of which indicates a
high correlation between the basal contractile ring and the apical domain.
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Figure 3.45. Pulsatile accumulation in the basal contractile ring and apical
translocation in the mutant where the 14-3-3"a–ERM interactions are in-
hibited. (2): (A, B) The basal ring intensity over time during phase II (15–17 hpf).
(A) Larva injected with ERM MO; (B) larva expressing 14-3-3"a C50-100:EGFP un-
der 14-3-3"a MO; (C, D) The cross-correlation analysis between the intensities of the
basal contractile ring and the apical domain. (C) Larva injected with ERM MO; (D)
larva expressing 14-3-3"a C50-100:EGFP under 14-3-3"a MO;
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3.2.10 Pulsatile basal accumulation and basal-apical transport
of 14-3-3"a and ERM is closely associated with those
of myosin II
The author next asked whether pulsatile basal accumulation and basal-apical transport
of 14-3-3"a and ERM is associated with movements of other cortical elements. The
author focused on non-muscle myosin II, which is known to be enriched in the basal
contractile ring and interacts with actin filaments to promote actomyosin contractility
that is critical for notochord cell elongation along the AP axis, and is also somehow
associated with lumen opening in the Ciona notochord [122, 138]. As previously de-
scribed [122], the myosin regulatory light chain fused to EGFP (MRLC:EGFP) showed
accumulation in the basal contractile ring. Extending these previous observations, the
author found that during phase II (15-17hpf), myosin II showed dynamic cycles of
pulsatile accumulation in the basal contractile ring, followed by directed basal-apical
flows through the cytoplasm (Fig. 3.46–3.49). Using two-color live imaging, the author
found that basal accumulation and basal-apical movements of myosin II were tightly
coordinated with those of 14-3-3"a and ERM (Fig. 3.46–3.49). These observations sug-
gest that local interactions between 14-3-3"a and ERM control pulsatile accumulation
and directed transport not just of themselves, but also of other cortically associated
factors.
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Figure 3.46. Kymograph analysis of the dynamics of myosin II (MRLC)
and 14-3-3"a: The placement of the cross-sections used to generate the kymograph
is indicated by white dashed lines. White triangles indicate the pulsed accumulation
of myosin II and 14-3-3"a.
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Figure 3.47. Pulsatile basal accumulation of myosin II and 14-3-3"a: The
intensity of myosin II and 14-3-3"a in the basal contractile ring over time. Yellow
arrowheads indicate the pulsatile accumulation of MRLC and 14-3-3"a.
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Figure 3.48. Myosin II translocate to the apical domain with 14-3-3"a (live
images): Live imaging of myosin II, 14-3-3"a, and their merging. White arrowheads
indicate the accumulation of myosin II and 14-3-3"a, showing translocation from the
basal contractile ring to the apical domain.
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Figure 3.49. Myosin II translocate to the apical domain with 14-3-3"a
(cross-correlation analysis): Cross-correlation analysis between the intensities of
the basal contractile ring and apical domain for myosin II and 14-3-3"a. The blue ar-
rowhead indicates the peak, the shift of which indicates a highest correlation between
the basal contractile ring and the apical domain.
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3.3 Discussion
Studies of Ciona notochord tubulogenesis have focused mainly on candidate genes that
are highly expressed in notochord cells or during tubulogenesis in other organisms. In
this study, the author took an in vivo chemical genetics approach to identify novel
genes that are responsible for Ciona notochord tubulogenesis. This in vivo chemical
genetics approach led us to identify UTKO1 to be a selective inhibitor of notochord
tubulogenesis (Fig. 3.2), to identify its target 14-3-3"a, and gain functional insights
into14-3-3"a’s role in notochord tubulogenesis
Because UTKO1 has been reported to inhibit tumor cell migration by targeting
14-3-3⇣, the author examined the possibility that UTKO1 also binds to Ciona 14-3-3.
In this study, in vitro binding assay clearly showed that among four 14-3-3 isoforms
in Ciona, UTKO1 selectively binds to 14-3-3"a (Fig. 3.13) through its 156–206-aa
domain (Fig. 3.22). Furthermore, 14-3-3"a KD resulted in failed lumen formation
in the notochord (Fig. 3.18), a similar phenotype to that observed following UTKO1
treatment. Therefore, this in vivo chemical genetics approach enabled us to identify 14-
3-3"a as a molecule responsible for Ciona notochord tubulogenesis. 14-3-3 proteins are
thought to exert their roles as adapter proteins that interact with various kinds of client
proteins. Here the author have identified Ciona ERM as a client protein through which
14-3-3"a exerts its e↵ects on notochord tubulogenesis. Ciona ERM is required for lumen
formation [122] and is predominantly expressed in the notochord [135,136]. In human
cell lines, ezrin interacts with 14-3-3⇣ to regulate cell migration [137]. Indeed, the
author found that 14-3-3"a interacted directly with ERM (Fig. 3.21) and colocalized
with ERM in the basal contractile ring (Fig. 3.26). Although the author cannot fully
rule out other possibilities, the inhibitory e↵ects of UTKO1 toward direct 14-3-3"a–
ERM interaction (Fig. 3.21), their colocalization (Fig. 3.26–3.27), and their dynamics
(Fig. 3.28–3.33) strongly suggest the involvement of ERM as a 14-3-3"a client protein
responsible for the early stage of Ciona notochord tubulogenesis.
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Live imaging analysis of 14-3-3"a and ERM in this study reveals fundamental in-
sights into their roles in lumen formation. Before lumen opening, 14-3-3"a and ERM
are stably co-enriched in a basal actomyosin ring (Fig. 3.28). However during lumen
opening and growth, the author find that 14-3-3"a and ERM undergo repeated cy-
cles of accumulation in the basal contractile ring, followed by rapid translocation from
the basal surface towards the lumen-facing apical domain (Fig. 3.29–3.33). These
movements are tightly correlated with movements of myosin II and other cytoplasmic
elements toward the apical surface, suggesting that they are carried as part of a bulk
flow of material from the basal surface to the apical lumen. (Fig. 3.34). Importantly,
neither pulsatile basal accumulation, nor directed basal-apical transport, nor lumen
formation, were observed when the 14-3-3"a–ERM interaction was destroyed by phar-
macological or genetic methods (UTKO1: Fig. 3.35–3.39; 14-3-3"a KD: Fig. 3.44, B,
D; ERM KD: Fig. 3.45, A, C; 14-3-3"a C50-100: Fig. 3.45, B, D). These findings
suggest that the 14-3-3"a–ERM interaction plays a key role in lumen formation by
directing transport of factors required for lumen growth to the apical surface (Fig.
3.50). Whether and how apical 14-3-3"a, ERM, or myosin II play secondary roles in
lumen formation, and what other lumen-associated molecules are transported by the
flow remains an interesting topic for future studies.
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Figure 3.50. Proposed models of lumen formation in Ciona notochord tubu-
logenesis via the interaction of 14-3-3"a and ERM: Orange coloring indicates
basal factors, including 14-3-3"a, ERM, myosin II and other cytoplasmic elements.
Blue arrowheads indicate cortical flows at the basal surface, directed towards the basal
equator, which would enable pulsatile accumulation in the basal contractile ring. Or-
ange arrowheads indicate a directed flow through the cytoplasm from the basal cortex
towards the lumen-adjacent apical domain. Gray arrowheads indicate the alteration of
the lumen architecture.
84
3.3 Discussion
The mechanisms by which 14-3-3"a–ERM governs pulsatile accumulation of basal
factors and their subsequent transport towards the apical surface of the growing lumen,
also remain unclear. An attractive possibility is that 14-3-3"a/ERM act by regulat-
ing pulsatile actomyosin contractility and cortical flow. Previous studies described
the recruitment of myosin II to the basal contractile ring via cortical flows directed
from cell-cell contacts towards the ring [124]. Observations in this study are consistent
with the possibility that pulsatile contraction and flow of cortical actomyosin II drives
accumulation of both myosin II and 14-3-3"a/ERM in the basal contractile ring. In
principle, actomyosin contractility could also drive their detachment from the mem-
brane, a contraction of cytoplasmic actomyosin could drive their basal-apical transport
through the cytoplasm. ERM proteins are known to tether the actomyosin network
directly to the plasma membrane and to regulate cortical tension and flow in other con-
texts [139–142]. 14-3-3 proteins can also associate with myosin II to regulate cortical
tension and flow [143–145]. The observation that pulsatile basal accumulation of 14-3-
3"a/ERM and their subsequent basal-apical translocation are abolished by removing
either protein or preventing their interactions (UTKO1: Fig. 3.35–3.39; 14-3-3"a KD:
Fig. 3.44, B, D; ERM KD: Fig. 3.45, A, C; 14-3-3"a C50-100: Fig. 3.45, B, D) is con-
sistent with the idea that 14-3-3"a/ERM interact to promote actomyosin contractility,
and raise the intriguing possibility that pulsatile contraction of the basal cortex and
transient apical-basal flows could be coupled through local regulation of actomyosin
contractility by 14-3-3"a/ERM.
This study reveals a key role for 14-3-3"a/ERM in lumen formation (Fig. 3.50).
The basal contractile ring also plays crucial roles in cell elongation along the A/P
axis [122,124,146], which may explain the short-tail phenotype caused by UTKO1 (Fig.
3.5). In Ciona and other tubulogenesis processes, cell elongation and lumen formation
are closely related [122, 147, 148]. Thus, by promoting both basal contraction and
cortical flow, and basal-apical cytoplasmic flow, 14-3-3"a–ERM in the basal contractile
ring would play roles in both cell elongation and lumen formation. Until now, lumen
formation in the Ciona notochord has mainly been investigated by focusing on apically
localizing molecules such as Par-3/Par-6/aPKC or Slc26a↵, as well as ERM itself.
Future studies of the mechanisms of basal contractility and directed flow will provide
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molecular or mechanical insights into tubulogenesis, bridging the gap between these
two opposite domains.
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3.4 Materials and Methods
3.4.1 Biological Materials
Ciona robusta were cultivated in Maizuru (Kyoto), Misaki (Kanagawa), and Shinya-
masita (Kanagawa). Adults were maintained under constant light to induce oocyte
maturation. Eggs and sperm were obtained by dissecting the gonadal and sperm ducts,
respectively. Eggs were dechorionated using a dechorionation reagent containing 0.05%
Actinase E (Kaken Pharmaceutical, Tokyo, Japan) and 1% mercaptoacetic acid sodium
salt (Wako Pure Chemical Industries, Osaka, Japan) in sea water, and cross fertiliza-
tion was performed in plastic Petri dishes. After fertilization, embryos were cultured
at 18 C. The onset of notochord tubulogenesis was at approximately 12 hpf.
3.4.2 Chemicals and antibodies
UTKO1 and its analogues were synthesized as previously described [129,130] and dis-
solved in methanol. Biotin was purchased from Sigma (St Louis, USA). For the gen-
eration of 14-3-3"a and ERM antibodies, the short peptide “EQMKKIAQLGISLT”,
for 14-3-3"a, and “KQIRSGNTKHRIDEFEC”, for ERM, were used for immunization
of rabbits and chickens, respectively. GST and a-pan-14-3-3 antibody were purchased
from Santa Cruz Biotechnology (California, USA), and His and GFP antibody were
obtained from Clontech (California, USA).
3.4.3 Imaging
Confocal images for phalloidin staining were prepared as previously described [61].
For the immunohistochemistry analysis, Ciona larvae were fixed with 10% formalin
in seawater for 30 min. They were washed several times with 0.1% Triton-X in PBS
(PBST) and blocked with 10% donkey serum in PBST for 2 h. The antibody for 14-3-
3"a and ERM was added, and the samples were incubated for 2 h. After several washes
in PBST, they were incubated with the second antibody for 2 h, and again washed
several times in PBST. For 14-3-3"a and GFP staining, the signal was amplified using
Tyramide SuperBoost Kits with Alexa Fluor Tyramides (Invitrogen, California, USA),
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according to the manufacturers instructions. These specimens were photographed using
a confocal laser scanning microscope system FV1000 (Olympus, Tokyo, Japan). Live
imaging was performed by fixing living Ciona larvae with 2% Agarose S (Wako Pure
Chemical Industries, Osaka, Japan) in seawater.
3.4.4 Plasmid construction
Ci-14-3-3s ("a, "b,  1 and  2) were amplified by PCR from cDNA library using a
pair of primers containing FLAG tag sequence, 5’-CGCGGATCCCTGATTACAAG
GATGACGACGATAAGATGTCTACTGAGCGCGAGGA-3’ and 5’-CCGGAATTC
TCTAGATTATGACGCTTCAGTGGCAT-3’ for Ci-14-3-3"a, 5’-CGCGGATCCCT
GATTACAAGGATGACGACGATAAGATGTCTACTGAACGTGAAGA-3’ and 5
’-CCGGAATTCTCTAGATTAAGGCTCATCATTTGCAT-3’ for Ci-14-3-3"b, 5’-C
GCGGATCCCTGATTACAAGGATGACGACGATAAGATGTCGTCAAGAGAAG
ACAT-3’ and 5’-CGCGGATCCTTAATCTTCAGTGTCCTGTA-3’ for Ci-14-3-3 1,
and 5’-CCGGAATTCAGATTACAAGGATGACGACGATAAGATGGCTGACGAT
CGTGATAC-3’ and 5’-CCGGAATTCTCTAGACTAATCCTCACACTGCGGGT-3’
for Ci-14-3-3 2. They were cloned into pGEX-3X (GE Healthcare, Little Chalfont,
UK) or pRSET-C (Invitrogen) to prepare GST or His fusion 14-3-3 proteins in E.
coli. ERM was obtained from Bra>ERM:EGFP [136] and cloned into pCold-I to
prepare the expression plasmids for the His fusion ERM protein in E. Coli. To prepare
Bra>14-3-3"a:EGFP and Bra>mCherry:ERM, the sequences for 14-3-3"a and ERM
were introduced to Bra>EGFP [136] and Bra>mCherry, which was modified from
Bra>EGFP. 14-3-3"a MO-resistant expression plasmids were prepared by introducing
mutations in Bra>14-3-3"a:EGFP using the following primers: 5’-ATGAGCACAGA
ACGCGAGGACTTTGTA-3’ and 5’-GCGTTCTGTGCTCATCTGCAGAATTCG-
3’.
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3.4.5 In vitro biotin-UTKO1 pull-down assay and western
blotting
Lysate of Ciona larvae at 15 hpf, or GST fusion proteins, which were expressed in
the E. coli BL21 strain and purified using Glutathione-Sepharose 4B (GE Healthcare),
were incubated with B-UTKO1ox/B-UTKO1ph and avidin beads in IP bu↵er (50 mM
HEPES, pH 7.5, 150 mM NaCl, 1 mM EDTA, 2.5 mM EGTA, 1 mM DTT, 10% glyc-
erol, and protease inhibitor cocktail). The beads were washed with IP bu↵er and PBS
and eluted with 2 mM biotin in PBS, all at 4 C. The eluted proteins were subjected
to SDS-PAGE. Proteins were detected using an ECL western blotting system (Milli-
pore) and an LAS-1000 CCD camera (Fujifilm, Tokyo, Japan) or the ChemiDoc XRS+
System (BioRad, Hercules, CA). For the competition assay, UTKO1 was added before
incubating the samples with B-UTKO1ox.
3.4.6 Microinjection of morpholino oligonucleotide
Morpholino anti-sense oligonucleotides (MO) were purchased from Gene Tools, LLC
(Philomath, OR): 5’-CAAAGTCCTCGCGCTCAGTAGACAT-3’ for Ci-14-3-3"a, 5’
-CCAAGTCTTCACGTTCAGTAGACAT-3’ for Ci-14-3-3"b, 5’-CTATCATGTCTT
CTCTTGACGACAT-3’ for Ci-14-3-3 1, and 5’-GATCGTCAGCCATCCTTCTGGG
TTT-3’ for Ci-14-3-3 2. The unfertilized eggs were injected with a mixture of 0.5 mM
MO and Fast Green or Phenol red as dye. A standard control MO from GeneTools
was used as negative control.
3.4.7 Binding assay for ERM and 14-3-3 proteins
GST-14-3-3"a (50 pmol) was incubated with or without UTKO1/UTKO10 for 1 h,
incubated with His-ERM (100 pmol) in 300 µl of IP bu↵er for 2 h, and incubated with
cOmplete His-tag purification resin (Roche, Basel, Switzerland) for 30 min. Beads were
washed three times with IP bu↵er and eluted with elution bu↵er containing 250 mM
imidazole in IP bu↵er. Eluted proteins were subjected to SDS-PAGE.
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3.4.8 RNA extraction and quantitative real-time PCR
Total RNA was prepared using TRIzol Reagent (Invitrogen), and cDNA was produced
using M-MLV H-point mutant reverse transcriptase (Promega), according to the manu-
facturer’s instructions. Quantitative real-time RT-PCR was carried out on cDNA using
SYBR premix Ex Taq (Takara, Shiga, Japan), detected by a Thermal Cycler Dice Real
Time System II (Takara), and analyzed using Smart Cycler software. The following
primer sets were used for real-time PCR: 5’-GCAAGTGATGCAGCAGGTAA-3’ and 5
’-AAAGCTTCCTTGGCCAATCT-3’ for 14-3-3"a; and 5’-GCAACCAAGAAAAAGC
TTGC-3’ and 5’-CTGCGGGTCATTATCAGCTT-3’ for glyceraldehyde-3-phosphate
dehydrogenase (GAPDH, internal control).
3.4.9 Image Processing and the quantification
The author used the open-source program Fiji to perform all basic image processing
tasks, to quantify the average signal intensities of the region of interest (ROI), to mea-
sure the size of the ROI, and to calculate the correlation coe cient for the colocalization
tests. In live imaging, the TurboReg plugin was used to register frames to prevent the
apparent blurring of the images. To generate kymographs with a heat map in live
imaging, the intensities in the basal domain surrounded by the ROIs were quantified
and normalized along the AP axis for every time point. Subsequently, kymographs
were generated by Fiji. Finally, colors were annotated using the Python programming
language to generate the heatmap, showing a gradient color scale from red, indicating
relatively high intensity, to blue, indicating relatively low intensity. To conduct a cross
correlation analysis, ROIs for the basal contractile ring and the apical domain were
manually set for each period (200 sec) and their cross correlation was calculated with
MATLAB (MathWorks).
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The importance of chemical biology has been recognized by cell biologists in recent
years. However, its application to developmental biology is not so common. In this
thesis, the author performed two chemical biological studies using ascidian Ciona ro-
busta, which have been a powerful model system in which to uncover basic mechanisms
that govern body plan specification and elaboration. As summarized below, the author
obtained results that would be useful in both applied research and basic research.
In Chapter 2, the author performed chemical toxicity evaluation using Ciona. The
dynamic phenotypic change of Ciona larvae during metamorphosis prompted the au-
thor to examine the e↵ect of cytotoxic drugs on its development by quantifying six
toxicity endpoints: degenerated tail size, ampulla length, rotation of body axis, stom-
ach size, heart rate, and body size. As a result, mitochondrial respiratory inhibitors,
tubulin polymerization/depolymerization inhibitors, or DNA/RNA synthesis inhibitors
showed distinct toxicity profiles against these six endpoints, but drugs with the same
targets showed a similar toxicity profile in Ciona. These results suggest Ciona is an ef-
fective animal model for profiling drug toxicity and exploring the mechanisms of drugs
with unknown targets.
In Chapter 3, the author applied chemical genetics to Ciona. Phenotypic screening
of the chemical compounds identified a selective inhibitor of notochord tubulogenesis,
UTKO1. This enabled the author to identify unbiasedly 14-3-3"a as a direct binding
partner of UTKO1 and showed that 14-3-3"a-knockdown leads to failure of notochord
tubulogenesis. To investigate how 14-3-3"a play roles for lumen formation, the author
focused on ERM, which is also known to be required for notochord tubulogenesis in
Ciona, as a possible 14-3-3"a client protein. The author found that UTKO1 prevents
14-3-3"a from interacting with ERM, suggesting that interactions between 14-3-3"a
and ERM play a key role in regulating the early steps of tubulogenesis. Live imaging
showed that as lumens begin to open between neighboring cells, 14-3-3"a and ERM
are highly colocalized at the basal cortex where they undergo cycles of accumulation
and disappearance. Interestingly, the disappearance of 14-3-3"a and ERM during each
cycle is tightly correlated with a transient flow of 14-3-3"a, ERM, myosin II and other
cytoplasmic elements from the basal surface towards the lumen-facing apical domain,
which is often accompanied by visible changes in lumen architecture. Both pulsatile
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flow and lumen formation are abolished in larvae treated with UTKO1, in larvae de-
pleted of either 14-3-3"a or ERM, or in larvae expressing a truncated form of 14-3-3"a
that lacks the ability to interact with ERM. These results suggest that 14-3-3"a and
ERM interact at the basal cortex to direct pulsatile basal accumulation and basal-
apical transport of factors that are essential for lumen formation. Because many core
components of this system are highly conserved, the author proposes that similar mech-
anisms may underlie or make contribute to lumen formation in tubulogenesis in other
systems.
These results suggest the usefulness of in vivo chemical biology studies using Ciona.
In chapter 2, the author showed that Ciona can be used as a toxicity evaluation animal
in applied research. Not only for that, the author also found that Ciona could profile
the toxicity of drugs, suggesting that Ciona could be used to gain insights into their
mode of action in basic research. In chapter 3, the molecular mechanisms underlying
Ciona notochord tubulogenesis was examined by chemical genetics which has commonly
been used in in vitro cell biology, but not in vivo developmental biology. This in vivo
chemical genetics approach highlight some of the features for elucidating the molecu-
lar mechanisms underlying the biological events. First, unbiased phenotypic screening
enabled the author to identify novel molecules responsible for the phenotype. The
author successfully identified 14-3-3"a as a responsible molecule for Ciona notochord
tubulogenesis by identifying UTKO1. This is in contrast to the previous studies where
novel genes for Ciona notochord tubulognenesis have been identified by candidate gene
strategy based on the expression profiles or the information in other systems. Further-
more, the use of chemical compounds enabled the author to examine the functional
roles of genes in space and time. The inhibition of the interaction between 14-3-3"a and
ERM by UTKO1 in vitro (Fig. 3.21) and in vivo (Fig. 3.26) identified key subcellular
region (basal contractile ring) that had been not so much paid attention. As a result,
the author found a novel phenomena (directed flow from the basal domain to apical
domain) for lumen formation during tubulogenesis. This study would be an important
first step to complehend the mechanisms underlying tubulogenesis, not only in Ciona
notochord but also in other systems. Therefore, chemical genetics is a powerful ap-
proach to elucidate the molecular mechanisms underlying biological events, and should
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be added to the option for the future research method in developmental biology. Taken
together, the author concludes that in vivo chemical biology using Ciona provides us
a lot of benefits in applied and basic research.
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教授 渡邉秀典博士， 高取聡美氏に深く御礼申しあげます．
著者が学部四年生の時からケミカルバイオロジー研究室の先輩として研究面・生活面に
おけるあらゆることを一からご指導くださいました, 卒業生 新荘聡子博士に深く感謝の
意を表します．
ホヤの脊索管形成の研究は，ケミカルバイオロジー研究室の卒業生 鈴木麻友 博士の研
究結果があったからこそ発展させることができました．心から感謝申し上げます．
ホヤの毒性試験の研究は，ケミカルバイオロジー研究室の卒業生 伊藤俊氏の研究結果
があってはじめて論文にまとめることができました．深く感謝いたします．
ホヤはナショナルバイオリソースプロジェクト(NBRP)から供与したいただきました．毎週
ホヤを郵送して下さいました，東京大学及び京都大学の関係者様に深く感謝申し上げます．
ERMのプラスミド鋳型を供与いただきました，基礎生物学研究所助教 高橋弘樹博士に
感謝の意を表します．
本研究の画像処理解析において，慶應義塾大学理工学部生命情報学科システム生物
学研究室 吉見祐亮氏，西本勝利氏にご指導いただきました．まことに感謝いたします．
日本学術振興会(JSPS)には特別研究員として二年間採用していただきました．不自由な
く生活し，自由に研究する機会を与えてくださいましたことに感謝の意を表します．
給費奨学生として奨学金を賜りました慶應義塾大学，慶應工学会，また貸与奨学生とし
て奨学金を賜りました日本学生支援機構奨学金に厚く御礼申し上げます．
平成25年度に研究員として四ヶ月雇用していただきました「卓越した大学院拠点形成支
援事業」に感謝の意を表します．
物品購入，旅費の手続きなど，幅広い面でサポートしていただいたケミカルバイオロジー
研究室秘書 梅崎秀香氏に厚く御礼申し上げます．
共にケミカルバイオロジー研究室で切磋琢磨し，互いを高めあった後期博士課程におけ
る同期の井岡秀二博士，齋藤駿博士，四方雄貴博士，前期博士課程における同期の大
嶽弘之氏，笠松誠人氏に深く感謝いたします．
共に後期博士課程に進んだ身として接する機会が多かったバイオインフォマティクス研
究室 青戸良賢氏，生物物理・神経情報学研究室 設楽久志博士からは研究面で大いに
刺激を受けました．まことに感謝いたします．
ケミカルバイオロジー研究室の先輩の皆様からは多くのことを学ばせていただきました．
少しでも著者が研究者として成長できているとするのなら，それは皆様が築いてくださ
ったケミカルバイオロジー研究室の文化の賜物です．厚く感謝いたします．
著者が直接研究を指導する機会をいただきました寺尾梢氏，有馬暁澄氏，手塚亮氏を
はじめ後輩の皆様からは逆に教えられることも多く，著者の身を引き締めてくださいました．
厚く感謝いたします．
生物物理・神経情報研究室の皆様全員，特にホヤ班の卒業生 中村允博士，山本彩加氏，
菊池恵理華氏，横山貴星氏，小泉航氏，中山友里氏，今井太一氏，村岡宏望氏，在校生 
赤星太一氏，Raphaël Gelin-Alessi氏，松村薫氏からは他研究室にも関わらず著者を
温かく迎えくださり，心地良く研究させていただきました．心より御礼申し上げます．
これまでお世話になった全ての友人に感謝します．特に慶應義塾大学ウインドアンサンブ
ルの同期パ トーであった入谷健資氏，白須鉱一氏，杉山翠氏，また学部一年時より同クラ
スで親交が深かった菅野一樹氏，安元雅俊氏には精神面で励ましていただきました．厚
く御礼申し上げます．
最後に，実に長い学生生活を辛抱強く支え，応援しつづけてくれた両親，祖母に心より感
謝いたします．
